Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Associate Professor of Medicine. Dr. Satlin received his M.D. from the University of Virginia and completed residency training in Internal Medicine and fellowship training in Infectious Diseases at Weill Cornell Medical College. He also received a Master's Degree in Clinical and Translational Investigation at Weill Cornell.

He is Clinical Director of the Transplantation-Oncology Infectious Diseases Program at Weill Cornell and provides infectious diseases supportive care to immunocompromised hosts. Dr. Satlin's research interests are in the epidemiology, diagnosis, and treatment of multidrug-resistant Gram-negative bacterial infections in immunocompromised hosts, and his research is supported by grants from NIAID and industry. He is Co-Chair of the Breakpoint Working Group of the Clinical and Laboratory Standards Institute's Subcommittee on Antimicrobial Susceptibility Testing and participates on multiple committees of NIAID's Antibacterial Research Leadership Group. He also serves as Associate Editor for Journal of Antimicrobial Chemotherapy-Antimicrobial Resistance and on the Editorial Advisory Boards of Clinical Infectious Diseases and Open Forum Infectious Diseases.

Highlights

  1. 1
    The Lancet. Microbe · 2023
    MSMichael Satlin
    PMID: 36774938PMCID: PMC10016089DOISenior author317 citations
  2. 2
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    MSMichael Satlin
    PMID: 32052041DOIFirst author223 citations
  3. 3
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    MSMichael Satlin
    PMID: 31504338DOIFirst author63 citations

Publications

145 publications

Funding

18 grantsView NIH portfolio on RePORTER ↗

Active

10 grants
  • Co-I
    Development of Targeted Antipseudomonal Bactericidal Prodrugs
    National Institute of Allergy and Infectious Diseases · 2023–2028 · via Cornell University - Ithaca
    R01AI174461-01A1
  • Sub-PI
    Optimizing escalation: Ceftolozane/tazobactam versus treatment with traditional anti-pseudomonal β-lactams for pneumonia or bloodstream infections due to MDR P. aeruginosa (STEWARDS)
    Merck Sharp & Dohme LLC · 2025–2027 · via University of PittsburghContract
    SRA 243556-01
  • Co-I
    Combatting Hospital-Acquired Carbapenem-Resistant Organism Infections in Cats
    EveryCat Health Foundation · 2026–2027 · via Cornell University
    CU 256123-01
  • PI
    Screening for Fluoroquinolone-Resistant Viridans Group Streptococci to Individualize Infection Prevention Strategies in Neutropenic Patients
    National Institute of Allergy and Infectious Diseases · 2024–2027
    R21AI182845-02
  • Co-I
    Microbial Biomarkers for Diagnosing and Predicting Infections in Kidney Transplant Recipients
    National Institutes of Health · 2024–2027 · via University of Pennsylvania· 2 renewals
    R01AI184528-03
  • PI
    In vitro Activity of Delafloxacin Against Viridians Group Streptococci Isolated from Neutropenic Patients
    Melinta Therapeutics, Inc. · 2026–2026Contract
    SRA 253345-01
  • Sub-PI
    Ceftazidime-Avibactam versus Meropenem-Vaborbactam for the treatment of bloodstream infections and/or pneumonia due to carbapenem-resistant Enterobacterales (CAMEL)
    Melinta Therapeutics, Inc. · 2026–2026 · via University of PittsburghContract
    SRA 253751-01
  • MPI
    Antibacterial Resistance Leadership Group (ARLG)
    National Institute of Allergy and Infectious Diseases · 2016–2026 · via Duke University· 3 renewals
    UM1AI104681-14
  • Co-I
    Metagenomic profiling of urinary cell-free DNA to monitor urinary tract infection after kidney transplantation
    National Institute of Allergy and Infectious Diseases · 2020–2026 · via Cornell University - Ithaca
    R01AI151059-02
  • Sub-PI
    TBDR Mediated Cefiderocol Resistance in Psuedomonas
    National Institute of Allergy and Infectious Diseases · 2023–2025 · via Houston Methodist Research Institute
    R21AI175821-02
Completed grants (8)
  • PI
    Screening for Resistant Enteric Bacteria to Personalize Infection Prevention Strategies in Neutropenic Patients
    National Institute of Allergy and Infectious Diseases · 2020–2025
    R01AI151038-04
  • Co-I
    "Performance comparison of rapid Antimicrobial Susceptibility Test (AST) system for clinical isolate colonies" SRA with Selux Diagnostics
    Selux Diagnostics · 2022–2024Contract
    SA 225932-01
  • PI
    Predicting Infections in Neutropenic Hosts Receiving Fluoroquinolone Prophylaxis
    National Institute of Allergy and Infectious Diseases · 2020–2023
    R03AI146612-02
  • PI
    DETECTION OF IMPENDING INFECTIONS IN IMMUNOCOMPROMISED CANCER PATIENTS.
    Starr Cancer Consortium · 2020–2022
    I13-0013
  • Co-I
    Performance Evaluation of the LifeScale AST Rapid, Automated Antimicrobial Susceptibility System
    Affinity Biosensors LLC · 2020–2022Contract
    SRA 201975-01
  • Co-I
    Determining the role of antibiotic tolerance in antibiotic therapy failure
    Weill Cornell Medical College · 2021–2021
    WCMC 211765-01
  • Co-I
    Multiplex PCR Characterization of Gastrointestinal Pathogens in Immunosuppressed Transplant Patient
    BioFire Diagnostic, LLC · 2018–2021
    SRA 181751-01
  • PI
    Rapid Identification of Neutropenic Patients at High Risk of CRE Bacteremia
    National Institute of Allergy and Infectious Diseases · 2014–2020Career
    K23AI114994-05

Clinical research

13 studies

Active

7 studies
  • PI
    A Phase 3, Multicenter, Prospective, Randomized, Open-label Efficacy and Safety Study of Intravenous Brincidofovir Versus Intravenous Cidofovir for Treatment of Adenovirus Infection in Pediatric and Adult Subjects After Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
    PHASE3 · SymBio Pharmaceuticals Limited · OPEN TO ACCRUAL (as of 2026)
    Adenovirus Infections
    NCT07387367
  • PI
    Cardiovascular Infection diagnosis using Metagenomics and Predicting Approach to appropriate Clinical Testing: The IMPACT Study
    Baylor College of Medicine · OPEN TO ACCRUAL (as of 2025)
  • PI
    Ceftazidime-Avibactam versus Meropenem-Vaborbactam for the treatment of bloodstream infections and/or pneumonia due to carbapenem-resistant EnterobacteraLes (CAMEL)
    Melinta Therapeutics, Inc. · OPEN TO ACCRUAL (as of 2025)
  • PI
    A Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia Coli Pre-Transplant
    PHASE1; PHASE2 · SNIPR Biome ApS · OPEN TO ACCRUAL (as of 2025)
    E Coli Infections; Allogenic Transplant Patients
    NCT06938867
  • PI
    Coordinating Center:Optimizing escalation: Ceftolozane/tazobactam versus treatment with traditional anti-pseudomonal ß-lactams for pneumonia or bloodstream infections due to MDR P. aeruginosa
    University of Pittsburgh · OPEN TO ACCRUAL (as of 2024)
  • PI
    Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria gonorrhoeae
    Duke University · OPEN TO ACCRUAL (as of 2024)
  • PI
    Screening for Fluoroquinolone-Resistant Viridans Group Streptococci to Individualize Infection Prevention Strategies in Neutropenic Patients
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (6)
  • PI
    Viral characteristics and host responses to novel coronavirus SARS-2 infection
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
  • PI
    Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies (SCENE)
    Duke University · CLOSED TO ACCRUAL (as of 2023)
    Hematologic Malignancy; Leukemia, Acute; Neutropenia; Bloodstream Infection
    NCT04710212
  • PI
    Coordinating Center: observational study to compare the effectiveness of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the United States (CACTUS)
    University of Pittsburgh · IRB STUDY CLOSURE (as of 2023)
  • PI
    Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies (SCENE)
    Duke University · CLOSED TO ACCRUAL (as of 2021)
    Hematologic Malignancy; Leukemia, Acute; Neutropenia; Bloodstream Infection
    NCT04710212
  • PI
    MDRO: Study of Highly Resistant Escherichia Coli
    Duke University · IRB STUDY CLOSURE (as of 2021)
    E Coli Infection
    NCT04574596
  • PI
    Individual Patient Access IND for Emergency Use of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter baumannii-calcoaceticus Complex
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2021)

News mentions

1 mentionView all WCM news ↗

Mentoring

2 menteesAll publications with mentees →

External relationships

Professional Services

AbbVie Inc.

Other

Beckman Coulter